» Articles » PMID: 37446900

An Amperometric Biosensor Based on a Bilayer of Electrodeposited Graphene Oxide and Co-Crosslinked Tyrosinase for L-Dopa Detection in Untreated Human Plasma

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 Jul 14
PMID 37446900
Authors
Affiliations
Soon will be listed here.
Abstract

L-Dopa, a bioactive compound naturally occurring in some Leguminosae plants, is the most effective symptomatic drug treatment for Parkinson's disease. During disease progression, fluctuations in L-DOPA plasma levels occur, causing motor complications. Sensing devices capable of rapidly monitoring drug levels would allow adjusting L-Dopa dosing, improving therapeutic outcomes. A novel amperometric biosensor for L-Dopa detection is described, based on tyrosinase co-crosslinked onto a graphene oxide layer produced through electrodeposition. Careful optimization of the enzyme immobilization procedure permitted to improve the long-term stability while substantially shortening and simplifying the biosensor fabrication. The effectiveness of the immobilization protocol combined with the enhanced performances of electrodeposited graphene oxide allowed to achieve high sensitivity, wide linear range, and a detection limit of 0.84 μM, suitable for L-Dopa detection within its therapeutic window. Interference from endogenous compounds, tested at concentrations levels typically found in drug-treated patients, was not significant. Ascorbic acid exhibited a tyrosinase inhibitory behavior and was therefore rejected from the enzymatic layer by casting an outer Nafion membrane. The proposed device was applied for L-Dopa detection in human plasma, showing good recoveries.

Citing Articles

Ethylenediamine assist preparation of carbon dots with novel biomass for highly sensitive detection of levodopa.

Huang Z, Li J, Li L RSC Adv. 2025; 15(1):420-427.

PMID: 39758905 PMC: 11697296. DOI: 10.1039/d4ra08240k.


Sensing the Future-Frontiers in Biosensors: Exploring Classifications, Principles, and Recent Advances.

Manoharan Nair Sudha Kumari S, Thankappan Suryabai X ACS Omega. 2024; 9(50):48918-48987.

PMID: 39713646 PMC: 11656264. DOI: 10.1021/acsomega.4c07991.


Biochemical Sensors for Personalized Therapy in Parkinson's Disease: Where We Stand.

Ciarrocchi D, Pecoraro P, Zompanti A, Pennazza G, Santonico M, di Biase L J Clin Med. 2024; 13(23).

PMID: 39685917 PMC: 11641839. DOI: 10.3390/jcm13237458.


L. Pod Valves: A By-Product with High Potential as an Adjuvant in the Treatment of Parkinson's Disease.

Tesoro C, Lelario F, Piscitelli F, Di Capua A, Della Sala P, Montoro P Molecules. 2024; 29(16).

PMID: 39203021 PMC: 11357479. DOI: 10.3390/molecules29163943.

References
1.
Galvan A, Wichmann T . Pathophysiology of parkinsonism. Clin Neurophysiol. 2008; 119(7):1459-74. PMC: 2467461. DOI: 10.1016/j.clinph.2008.03.017. View

2.
Coello J, Maspoch S, Villegas N . Simultaneous kinetic-spectrophotometric determination of levodopa and benserazide by bi- and three-way partial least squares calibration. Talanta. 2008; 53(3):627-37. DOI: 10.1016/s0039-9140(00)00539-7. View

3.
Ribeiro R, Gasparetto J, Vilhena R, de Francisco T, Martins C, Cardoso M . Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method. Bioanalysis. 2015; 7(2):207-20. DOI: 10.4155/bio.14.230. View

4.
Tong Q, Zhang L, Yuan Y, Jiang S, Zhang R, Xu Q . Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms. Parkinsonism Relat Disord. 2015; 21(8):882-7. DOI: 10.1016/j.parkreldis.2015.05.016. View

5.
Paul R, Borah A . L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room. Biochim Biophys Acta. 2016; 1860(9):1989-97. DOI: 10.1016/j.bbagen.2016.06.018. View